Zura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short Interest

Zura Bio Limited (NASDAQ:ZURA) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 1,860,000 shares, a growth of 118.9% from the September 15th total of 849,700 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average trading volume of 473,800 shares, the short-interest ratio is currently 3.9 days.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ZURA shares. Piper Sandler restated an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. HC Wainwright initiated coverage on Zura Bio in a research report on Thursday, September 5th. They set a “neutral” rating and a $5.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Thursday, August 15th.

Insider Activity at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares of the company’s stock, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 22.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in Zura Bio during the second quarter worth approximately $8,446,000. Great Point Partners LLC increased its stake in shares of Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after acquiring an additional 1,884,501 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after acquiring an additional 876,000 shares during the period. Affinity Asset Advisors LLC acquired a new position in shares of Zura Bio during the 1st quarter valued at about $1,157,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Zura Bio in the third quarter valued at about $62,000. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Stock Performance

Zura Bio stock opened at $3.86 on Friday. The stock’s 50 day simple moving average is $3.82 and its two-hundred day simple moving average is $3.87. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.92.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, equities research analysts expect that Zura Bio will post -0.47 earnings per share for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.